Multicenter, Observational Study of Lanreotide Autogel for the Treatment of Patients with Neuroendocrine Tumors in Routine Clinical Practice in Germany and Austria

Rinke A, Maintz C, Muller L, Weber MM, Lahner H, Pavel ME, Saeger W, Houchard A, Ungewiss H, Petersenn S (2021)

Publication Type: Journal article

Publication year: 2021

Journal

Experimental and Clinical Endocrinology and Diabetes Thieme Publishing

Book Volume: 129

Pages Range: 500-509

Journal Issue: 7

DOI: 10.1055/a-1342-2755

Abstract

Background The long-acting somatostatin analog lanreotide autogel is effective in the treatment of patients with neuroendocrine tumors. Objective To evaluate the long-term treatment response in patients with neuroendocrine tumors receiving lanreotide autogel in routine clinical practice. Methods Non-interventional, 24-month study in patients with neuroendocrine tumors treated with lanreotide autogel (NCT01840449). Results Patients (n=80) from 26 centers in Germany and Austria were enrolled. Neuroendocrine tumors were mainly grade 1/2, metastasized, intestinal, and associated with carcinoid syndrome; 88.9% had received previous neuroendocrine tumor treatment. Of those, 84.4% had previous surgery, 18.7% had received octreotide. The primary endpoint, defined by a <50% chromogranin A increase at month 12 compared with the lowest value between baseline and month 3 was achieved by 89.5% patients. Stable disease according to Response Evaluation Criteria in Solid Tumors 1.1 was observed in 76.9 and 75.0% patients at months 12 and 24 of lanreotide treatment, respectively. Mean change of chromogranin A levels from baseline to month 24 was -0.12 × upper limit of normal (95% CI, -0.22; -0.45). In a post hoc analysis, 38.5% of the subgroup of patients with carcinoid syndrome had daily diarrhea at baseline vs. 21.4% at month 24. At baseline, 27.8% of patients received lanreotide 120 mg every 4 weeks vs. 56.7% at month 24. Quality of life data were heterogeneous. No new safety issues arose and/or required further investigation. Conclusions Our study reflects routine lanreotide autogel use in patients with advanced/metastatic neuroendocrine tumors. This analysis shows effectiveness with stabilization of disease-related symptoms and good tolerability of lanreotide autogel in clinical practice.

Authors with CRIS profile

Marianne Ellen Pavel Department of Medicine 1 – Gastroenterology, Pneumology and Endocrinology

Involved external institutions

Universitätsklinikum Essen DE Germany (DE) Universitätsklinikum Gießen und Marburg (UKGM) DE Germany (DE) Johannes Gutenberg-Universität Mainz (JGU) DE Germany (DE) ENDOC Praxis für Endokrinologie, Andrologie und medikamentöse Tumortherapie DE Germany (DE) Ipsen Pharma FR France (FR) Universitätsklinikum Hamburg-Eppendorf (UKE) DE Germany (DE)

How to cite

APA:

Rinke, A., Maintz, C., Muller, L., Weber, M.M., Lahner, H., Pavel, M.E.,... Petersenn, S. (2021). Multicenter, Observational Study of Lanreotide Autogel for the Treatment of Patients with Neuroendocrine Tumors in Routine Clinical Practice in Germany and Austria. Experimental and Clinical Endocrinology and Diabetes, 129(7), 500-509. https://doi.org/10.1055/a-1342-2755

MLA:

Rinke, Anja, et al. "Multicenter, Observational Study of Lanreotide Autogel for the Treatment of Patients with Neuroendocrine Tumors in Routine Clinical Practice in Germany and Austria." Experimental and Clinical Endocrinology and Diabetes 129.7 (2021): 500-509.

BibTeX: Download